Abstract Number: 1070 • ACR Convergence 2024
Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) has been shown to decrease mortality. The American College of Radiology, European…Abstract Number: 2042 • ACR Convergence 2024
Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center
Background/Purpose: Sarcoidosis is a disease occurring in the form of non-caseating granulomas, with unclear etiology and multi-system manifestations. Pulmonary involvement in sarcoidosis is a cardinal…Abstract Number: 1377 • ACR Convergence 2023
Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study
Background/Purpose: Sjögren disease (Sjo) is a systemic immune-related disease with pulmonary manifestations occurring in up to 16% of patients [1], including interstitial lung disease (SS-ILD)…Abstract Number: 1821 • ACR Convergence 2023
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…Abstract Number: 0256 • ACR Convergence 2023
Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study
Background/Purpose: Japanese patients with connective tissue disease (CTD) are more likely to have interstitial lung disease (CTD-ILD) than those in Western countries and many CTD-ILDs…Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…Abstract Number: 1926 • ACR Convergence 2023
Use of 18F-FDG PET in Assessing Response to Treatment in Adults with Pulmonary Sarcoidosis: A Systematic Literature Review
Background/Purpose: Sarcoidosis is a chronic, multisystem, granulomatous disease commonly affecting the lungs. Immunosuppressants, particularly corticosteroids, are the mainstay of treatment. Symptoms, severity and response to…Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…Abstract Number: 1514 • ACR Convergence 2023
Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in connective tissue disorders (CTD) including rheumatoid arthritis, scleroderma and inflammatory myopathies.…Abstract Number: 1927 • ACR Convergence 2023
Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review
Background/Purpose: Anti-synthetase syndrome (ASS) is a chronic autoimmune inflammatory condition, characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud's phenomenon and mechanic's hands. This systematic…Abstract Number: 0358 • ACR Convergence 2023
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem with urgent unmet needs including prevalence, pathogenesis, disease…Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…Abstract Number: 0409 • ACR Convergence 2023
Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis
Background/Purpose: Pulmonary impairment is a common, yet poorly understood, extraarticular manifestation in rheumatic diseases, which is often inadequately screened and managed. This can result in…Abstract Number: 1530 • ACR Convergence 2023
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
Background/Purpose: Lung transplantation (LT) is gaining ground in managing advanced ILD in SSc patients. However, concerns remain among surgeons due to SSc's complexity, multiorgan involvement…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »